Dizal Pharmaceutical(SH:688192) Xin Lang Zheng Quan·2025-11-06 01:27Core Viewpoint - Dize Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with significant revenue growth but ongoing net losses, reflecting challenges in profitability despite strong sales growth [1][2]. Group 1: Stock Performance - On November 5, Dize Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 234 million yuan [1]. - The financing buy-in amount for Dize Pharmaceutical on the same day was 9.97 million yuan, while the financing repayment was 12.63 million yuan, resulting in a net financing outflow of 2.66 million yuan [1]. - As of November 5, the total balance of margin trading for Dize Pharmaceutical was 166 million yuan, which accounts for 0.58% of its market capitalization [1]. Group 2: Financial Performance - For the period from January to September 2025, Dize Pharmaceutical reported a revenue of 586 million yuan, representing a year-on-year growth of 73.23% [2]. - The company's net profit attributable to shareholders was -580 million yuan, showing a year-on-year decrease of 3.85% [2]. - As of September 30, 2025, the number of shareholders increased to 8,806, up by 5.01%, with an average of 46,528 circulating shares per person, an increase of 108.97% [2]. Group 3: Shareholder Composition - As of September 30, 2025, the fourth largest circulating shareholder was Yongying Pharmaceutical Innovation Mixed Fund A, holding 5.91 million shares, an increase of 2.30 million shares from the previous period [2]. - Hong Kong Central Clearing Limited entered as a new sixth largest shareholder with 4.51 million shares [2]. - Other notable changes include an increase in holdings by Dongfanghong Medical Upgrade Fund A and a decrease by Penghua Pharmaceutical Technology Fund A among the top ten circulating shareholders [2].